Delivery of the tumor antigens by MVs also modulate cross-presentation of those tumor glycosylated antigens such as MUC1 that are thought to induce only a tolerogenic CD4+ T cell response, although being relevant for tumor targeting (27). This evidence concerns the gene CD4 and neoplasm.